(Q30210342)

10 June 2017

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults (English)

1 reference

10 June 2017

0 references

5

Philip R Dormitzer

1 reference

10 June 2017

Stephan A Bart

1

1 reference

10 June 2017

Matthew Hohenboken

2

1 reference

10 June 2017

Giovanni Della Cioppa

3

1 reference

10 June 2017

Vas Narasimhan

4

1 reference

10 June 2017

Niranjan Kanesa-Thasan

6

1 reference

10 June 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

Science Translational Medicine

10 June 2017

1 reference

10 June 2017

6

1 reference

10 June 2017

234ra55

1 reference

10 June 2017

234

1 reference

A detailed epidemiological and clinical description of 6 human cases of avian-origin influenza A (H7N9) virus infection in Shanghai

10 June 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Population-level antibody estimates to novel influenza A/H7N9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Human infection with a novel avian-origin influenza A (H7N9) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Global concerns regarding novel influenza A (H7N9) virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

H7N9 influenza viruses are transmissible in ferrets by respiratory droplet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Continuous cell lines as a production system for influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Cell-culture-derived influenza vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Human antibody responses to avian influenza A(H7N9) virus, 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

A recombinant viruslike particle influenza A (H7N9) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Correlates of protection to influenza virus, where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

Reproducibility of serologic assays for influenza virus A (H5N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008761

10.1126/SCITRANSLMED.3008761

21 January 2018

Identifiers

DOI

1 reference

10 June 2017

1 reference